kinetic jaffe method (creatinine reagent kit, ref#: 07p99) (Abbott Laboratories)
90
Structured Review
Abbott Laboratories
kinetic jaffe method (creatinine reagent kit, ref#: 07p99)
Kinetic Jaffe Method (Creatinine Reagent Kit, Ref#: 07p99), supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/creatinine+reagent+kit+creatinine+(jaffe)/kinetic+jaffe+method++creatinine+reagent+kit++ref+++07p99+/pm39307881-46-9-18
Average 90 stars, based on 1 article reviews
Kinetic Jaffe Method (Creatinine Reagent Kit, Ref#: 07p99), supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/creatinine+reagent+kit+creatinine+(jaffe)/kinetic+jaffe+method++creatinine+reagent+kit++ref+++07p99+/pm39307881-46-9-18
Average 90 stars, based on 1 article reviews
kinetic jaffe method (creatinine reagent kit, ref#: 07p99) - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis. Article Snippet: 1 Clinical Laboratory Department, University and Polytechnic Hospital La Fe, Avinguda de Fernando Abril Martorell, 106, Quatre Carreres, Valencia 46026, Spain 2 Neuroimmunology Unit, University and Polytechnic Hospital La Fe, Valencia, Spain 3 Department of Didactic of Mathematics, University of Valencia, Valencia, Spain Abstract Background sNfL, a promising biomarker for neuroaxonal damage in Multiple Sclerosis (MS), requires cautious interpretation due to several comorbidity influences.. Objectives To investigate the impact of renal function on sNfL levels in MS patients.. Methods This retrospective study stratified patients by MS clinical phenotype, acute inflammatory activity (AIA) status— defined as relapse or gadolinium-enhancing lesions within 90 days of sample collection—renal function, assessed by estimated glomerular filtration rate (eGFR), and age (< 40 years, 40–60 years, > 60 years). |